Explore our corporate updates and press releases below. For the latest news, follow us on LinkedIn.
To learn more about our company, visit our Corporate Overview page. To see our progress toward new answers and disease-centric therapies, visit our Pipeline page or review recent articles and studies on our Publications page.
|07/07/2023||Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Trispecific Antibody, ISB 2001||Press Release|
|06/23/2023||Ichnos Sciences Welcomes Lida Pacaud, M.D., as New Chief Medical Officer||Press Release|
|03/20/2023||Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442||Press Release|
|12/12/2022||Ichnos Sciences Presents Data Supporting Three Oncology Assets at ASH 2022 Annual Meeting||Press Release|
|11/03/2022||Ichnos Sciences Data Selected for Presentation at the 64th ASH Annual Meeting||Press Release|
|09/28/2022||Ichnos Sciences Announces Initiation Of First-In-Human Study For ISB 1442||Press Release|
|06/07/2022||Ichnos Sciences To Present At The 2022 Jefferies Healthcare Conference||Press Release|
|05/09/2022||Ichnos Sciences Announces Selection of Trispecific Antibody ISB 2001 as Next Clinical Candidate for Relapsed/Refractory Multiple Myeloma||Press Release|
|04/19/2022||Ichnos Sciences Welcomes Ashok Marín As New General Counsel||Press Release|
|03/23/2022||Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting||Press Release|
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.